SCHEMBL7959516

SCHEMBL7959516

O=C1CC(C2COc3ccccc3C2)Oc2ccc(Br)cc21

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PBRM1 Q86U86 1/20 0.50
AR P10275 4/20 0.48
CYP19A1 P11511 2/20 0.46
SIGMAR1 Q99720 2/20 0.41
STS P08842 1/20 0.38
APP P05067 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
CYP3A4 P08684 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
MAOB P27338 2/20 0.36
MAOA P21397 1/20 0.36
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
HSD17B10 Q99714 1/20 0.35
RORC P51449 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1979482 0.79 PBRM1 (0.63) PBRM1ARCYP19A1SIGMAR1STS
SCHEMBL7949937 0.78 PGR (0.40) CYP19A1SIGMAR1STSRORC
SCHEMBL12247350 0.78 STS (0.37) ARSIGMAR1STSNPC1RAB9A
SCHEMBL1821203 0.76 STS (0.60) PBRM1ARCYP19A1SIGMAR1STS
SCHEMBL1824777 0.75 PBRM1 (0.57) PBRM1ARSTSRORC
SCHEMBL7962452 0.74 AR (0.52) PBRM1ARCYP19A1APPNPC1
SCHEMBL7962622 0.74 AR (0.54) PBRM1ARCYP19A1SIGMAR1STS
SCHEMBL16105864 0.73 PBRM1 (0.52) PBRM1ARCYP19A1STSAPP
SCHEMBL7968965 0.73 PBRM1 (0.52) PBRM1ARCYP19A1STSAPP
SCHEMBL1824234 0.73 PBRM1 (0.52) PBRM1ARCYP19A1STSAPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921359-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-12-30 US disclosed
US-8921359-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-12-30 US disclosed
EP-2324032-B1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS INC (US) 2014-10-01 EP disclosed
US-8450308-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2013-05-28 US disclosed
US-8450308-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2013-05-28 US disclosed
US-20110218192-A1 Inhibitors Of Beta-Secretase VITAE PHARMACEUTICALS, INC. (US) 2011-09-08 US disclosed
US-20110218192-A1 Inhibitors Of Beta-Secretase VITAE PHARMACEUTICALS, INC. (US) 2011-09-08 US disclosed
WO-2010021680-A2 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. (US) 2010-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110218192-A1 Inhibitors Of Beta-Secretase BACE1, BACE2, APP PBRM1 2309/4885AR 4331/4885CYP19A1 1456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.